-
Blood Cancer Awareness Month: Key Trends in the Hematology Oncology Market
Blood Cancer Awareness Month: Key Trends in the Hematology Oncology Market Dr. Andrew Merron, Executive Director, DRG Oncology For Blood Cancer Awareness Month, Dr. Andrew Merron discusses major...
-
Latest HPA findings reveal shifting dynamics in national and regional healthcare
As part of our effort to offer the very latest in Health Plan Analysis, DRG is pleased to offer this high-level view of our latest findings on national and regional trends. These insights offer an...
-
The Impact of Medical Devices on Healthcare Delivery – Challenges to and Benefits of Implementation
DRG conducted a literature review with the objective of identifying published examples of service impact and system design models for innovative non-pharmaceutical health technologies. This white...
-
Greater Accuracy in Market Sizing Using Epidemiology + Real-World Evidence
Greater Accuracy in Market Sizing Using Epidemiology + Real-World Evidence: The case for collaborative, agile research
-
Checkpoint Inhibitor Playbook – 8 Steps to Success
In recent years, we have seen transformational advances in oncology treatment thanks to the arrival of immune checkpoint inhibitors. Recent R&D focus on studying the benefits of combination...
-
Oncology Pulse - Oncology Clinical Trial Design - Impact of the Latest Industry Guidelines for Pharma
Oncology Clinical Trial Design - Impact of the Latest Industry Guidelines for Pharma Dr. Andrew Merron, Executive Director, DRG Oncology In August 2018, the FDA and ASCO released exciting new...
-
The Changing Face of Motor Symptom Treatment in Parkinson’s Disease
High unmet need for new drugs to address motor complications in Parkinson’s disease (PD) has attracted a number of developers to this space; since 2015, four new brands targeting motor symptoms have...
-
DRG Oncology Your Decisions Made Easier and Faster at Every Point of the Lifecycle
Key questions that oncology strategists need to look at across the drug lifecycle, and solutions for answering them confidently and quickly.
-
How Can Pharma Find Success in the Evolving Immune Checkpoint Inhibitor Pipeline?
The immune checkpoint inhibitor clinical landscape is bustling with activity, with more than 1,000 trials for currently available products scheduled to complete between 2018 and 2020. Despite the...
-
Orthopedic Device Markets in China: The Growing Threat from Domestic Competition
This live session took place on Tuesday, July 24, 2018. Rapid growth in the Chinese orthopedic market and large foreseeable opportunities have attracted significant investment from both multinational...
A global consultancy and training agency providing market leading product & portfolio strategy, health economic outcomes research & evidence generation, value communication and training services across the life science industry.
We partner with both the biopharmaceutical and medical technology industry to support commercialization & patient access across a variety of functions including: R&D, commercial strategy, HEOR, market access, new product planning, marketing, data insights & analytics, business development and channel & segment customer engagement.
